251 related articles for article (PubMed ID: 20822348)
1. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.
Paris RM; Kim JH; Robb ML; Michael NL
Expert Rev Vaccines; 2010 Sep; 9(9):1055-69. PubMed ID: 20822348
[TBL] [Abstract][Full Text] [Related]
2. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
[TBL] [Abstract][Full Text] [Related]
4. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
[TBL] [Abstract][Full Text] [Related]
5. AIDS vaccine development: the long and winding road.
Garber DA; Feinberg MB
AIDS Rev; 2003; 5(3):131-9. PubMed ID: 14598562
[TBL] [Abstract][Full Text] [Related]
6. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV.
Xin KQ; Jounai N; Someya K; Honma K; Mizuguchi H; Naganawa S; Kitamura K; Hayakawa T; Saha S; Takeshita F; Okuda K; Honda M; Klinman DM; Okuda K
Gene Ther; 2005 Dec; 12(24):1769-77. PubMed ID: 16079886
[TBL] [Abstract][Full Text] [Related]
7. Heterologous prime-boost vaccination strategies for HIV-1: augmenting cellular immune responses.
Newman MJ
Curr Opin Investig Drugs; 2002 Mar; 3(3):374-8. PubMed ID: 12054082
[TBL] [Abstract][Full Text] [Related]
8. Heterologous HIV-based lentiviral/adenoviral vectors immunizations result in enhanced HIV-specific immunity.
Asefa B; Korokhov N; Lemiale F
Vaccine; 2010 Apr; 28(20):3617-24. PubMed ID: 20051277
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1.
Ranasinghe C; Medveczky JC; Woltring D; Gao K; Thomson S; Coupar BE; Boyle DB; Ramsay AJ; Ramshaw IA
Vaccine; 2006 Jul; 24(31-32):5881-95. PubMed ID: 16759767
[TBL] [Abstract][Full Text] [Related]
10. Poxvirus vector-based HIV vaccines.
Pantaleo G; Esteban M; Jacobs B; Tartaglia J
Curr Opin HIV AIDS; 2010 Sep; 5(5):391-6. PubMed ID: 20978379
[TBL] [Abstract][Full Text] [Related]
11. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
12. Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans.
Bett AJ; Dubey SA; Mehrotra DV; Guan L; Long R; Anderson K; Collins K; Gaunt C; Fernandez R; Cole S; Meschino S; Tang A; Sun X; Gurunathan S; Tartaglia J; Robertson MN; Shiver JW; Casimiro DR
Vaccine; 2010 Nov; 28(50):7881-9. PubMed ID: 20937317
[TBL] [Abstract][Full Text] [Related]
13. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
[TBL] [Abstract][Full Text] [Related]
14. A prime-boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protective immunity against human respiratory syncytial virus.
Fu YH; He JS; Wang XB; Zheng XX; Wu Q; Xie C; Zhang M; Wei W; Tang Q; Song JD; Qu JG; Hong T
Biochem Biophys Res Commun; 2010 Apr; 395(1):87-92. PubMed ID: 20350532
[TBL] [Abstract][Full Text] [Related]
15. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
16. Chimeric adenovirus 5/35 vector containing the clade C HIV gag gene induces a cross-reactive immune response against HIV.
Xin KQ; Sekimoto Y; Takahashi T; Mizuguchi H; Ichino M; Yoshida A; Okuda K
Vaccine; 2007 May; 25(19):3809-15. PubMed ID: 17386962
[TBL] [Abstract][Full Text] [Related]
17. Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization routes.
Promkhatkaew D; Matsuo K; Pinyosukhee N; Thongdeejaroen W; Leang-Aramgul P; Sawanpanyalert P; Warachit P
Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):273-81. PubMed ID: 19323012
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.
Cristillo AD; Wang S; Caskey MS; Unangst T; Hocker L; He L; Hudacik L; Whitney S; Keen T; Chou TH; Shen S; Joshi S; Kalyanaraman VS; Nair B; Markham P; Lu S; Pal R
Virology; 2006 Mar; 346(1):151-68. PubMed ID: 16325880
[TBL] [Abstract][Full Text] [Related]
19. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates.
Santra S; Seaman MS; Xu L; Barouch DH; Lord CI; Lifton MA; Gorgone DA; Beaudry KR; Svehla K; Welcher B; Chakrabarti BK; Huang Y; Yang ZY; Mascola JR; Nabel GJ; Letvin NL
J Virol; 2005 May; 79(10):6516-22. PubMed ID: 15858035
[TBL] [Abstract][Full Text] [Related]
20. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
